Missing Data Hinders Inclusion Of Patient Experience In Drug Labeling, US FDA Says

 
• By Brenda Sandburg
  
Patient data
Missing data on trial endpoints can limit drug label claims • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

More from Agency Leadership